Institut De Recherches Internationales Servier

This early-phase study tests whether combining vorasidenib (a targeted therapy) with pembrolizumab (an immunotherapy) is safe and can boost the immune system's attack on recurrent IDH-1 mutant gliomas, a type of brain tumor. About 60 adults with grade 2 or 3 astrocytoma or oligod…

This study tests whether adding the targeted drug ivosidenib to standard azacitidine helps adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML) who cannot have strong chemotherapy. About 146 participants received either the drug combo or a placebo comb…

This study tests a new drug, vorasidenib, combined with a standard chemotherapy (temozolomide) in people with a specific type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to find the safest dose and see if the combination can help control the tumor. Abou…